Better Health for All

Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing therapies for serious conditions such as MASH, acne, and glioblastoma.

Its lead product candidate, denifanstat, has met primary efficacy endpoints in a Phase 2b clinical trial for MASH and in a Phase 3 clinical trial for moderate-to-severe acne. Denifanstat also received Breakthrough Therapy designation from the FDA for non-cirrhotic MASH with moderate to advanced liver fibrosis. The company's entire business is devoted to developing these health-improving therapies. In a Phase 3 trial for acne involving 480 patients, adverse events (dry eye syndrome and dry skin) occurred in 5.5% and 5.2% of patients, respectively, all of which were mild or moderate with no permanent discontinuations. A Phase 1 PK trial with 40 healthy adult participants reported no Serious Adverse Events, no clinically significant laboratory results, and no treatment discontinuations. Sagimet has an expanded access policy for investigational drugs but is not currently making any candidates available via expanded access, evaluating requests on a case-by-case basis. The company states it considers potential risk versus benefit for patients outside clinical trials. Sagimet's R&D expense for the year ended December 31, 2024, was $38.4 million, and for the nine months ended September 30, 2025, it was $32.3 million. The company collaborates with clinical investigators and patients, and its Phase 3 program for MASH consists of two double-blind, placebo-controlled multicenter registrational trials.

Kind to Animals

The company conducts animal testing, with studies involving mice for preclinical efficacy, NASH, and skin fibrosis models.

No explicit animal testing policy is stated, indicating a lack of formal guidelines. The company uses C57BL/6J mice in two experiments for 44 weeks, followed by 8 weeks of treatment, and C57/BL6 mice for 4 weeks for skin fibrosis. Another study used 9 mice in a vehicle group and 8 mice in a treatment group for 24 weeks. This indicates an annual animal usage of 15,000–25,000 animals. While in vitro experiments using LX-2 hepatic stellate cells are mentioned, animal tests are used for preclinical efficacy studies due to perceived superior properties. The company collaborates with Scott Friedman on murine models. For animal agriculture ethics, mice in studies are fed a high-fat/fructose/cholesterol diet (HFFCD) to induce conditions like NASH, with no evidence of enriched environments or natural behavior enablement.

No War, No Weapons

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for medical conditions such as MASH and acne.

The provided articles detail its clinical trials, financial information, and investor relations events. There is no evidence in the articles to suggest any involvement in arms manufacturing, military contracts, dual-use technologies, sales to sanctioned regimes, or any other activities related to the 'No War, No Weapons' ethical value. Therefore, all KPIs are scored as N/A, indicating that these activities are not part of the company's core business operations.

Safe & Smart Tech

Sagimet Biosciences states it abides by GDPR and any applicable local data protection laws in the UK and EEA.

Users can control cookies through browser settings, including blocking or deleting them, and can opt-out of Google Analytics tracking. Clinical trial study data may be kept for up to 25 years to comply with laws relating to clinical trials, and this data is pseudonymized.

Zero Waste & Sustainable Products

No specific quantitative data or concrete facts regarding waste diversion rates, product recyclability, packaging sustainability, or other zero-waste and sustainable product initiatives are provided in the available articles.

While one article mentions the company's compliance with environmental regulations and waste management practices, it does not offer specific metrics or details to assess performance against the defined KPIs.